The effect of intensive risk factor management in type 2 diabetes on inflammatory biomarkers

Xanthia F. Samaropoulos, Laney Light, Walter T. Ambrosius, Santica M. Marcovina, Jeffrey Probstfield, David C. Goff

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Aims: To determine whether intensive risk factor management reduced markers of inflammation in middle-aged and older people with type 2 diabetes who either had, or were at risk for cardiovascular disease (CVD), and whether these effects were mediated by adiposity. Methods: The Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial was a multicenter double 2 by 2 factorial randomized controlled trial of 10,251 middle-aged and older people who had type 2 diabetes, a GHbA1c of 7.5% or greater, and evidence of CVD or CVD risk factors. Biomarkers were assessed in a subset of 562 participants. Intervention effects on high-sensitivity C-reactive protein (hs-CRP), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-alpha) were tested using linear regression models. Results: A significantly lower average hs-CRP was noted in the intensive versus the standard glycemic group (p=0.029). Adjusting for change in BMI or waist circumference resulted in larger differences in adjusted hs-CRP (p<0.001 and p<0.002, respectively) between the glycemic intervention groups. Conclusions: Intensive glycemic control was associated with a reduction in hs-CRP in this study population. Intervention associated increases in adiposity suppressed the beneficial effect of intensive glycemic control on lowering hs-CRP.

Original languageEnglish (US)
Pages (from-to)389-398
Number of pages10
JournalDiabetes Research and Clinical Practice
Volume95
Issue number3
DOIs
StatePublished - Mar 1 2012

Fingerprint

Risk Management
C-Reactive Protein
Type 2 Diabetes Mellitus
Biomarkers
Cardiovascular Diseases
Adiposity
Linear Models
Waist Circumference
Interleukin-6
Randomized Controlled Trials
Tumor Necrosis Factor-alpha
Inflammation
Population

Keywords

  • ACCORD trial
  • Adiposity
  • CVD
  • Hs-CRP
  • Inflammation
  • Type 2 diabetes

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Internal Medicine
  • Endocrinology

Cite this

The effect of intensive risk factor management in type 2 diabetes on inflammatory biomarkers. / Samaropoulos, Xanthia F.; Light, Laney; Ambrosius, Walter T.; Marcovina, Santica M.; Probstfield, Jeffrey; Goff, David C.

In: Diabetes Research and Clinical Practice, Vol. 95, No. 3, 01.03.2012, p. 389-398.

Research output: Contribution to journalArticle

Samaropoulos, Xanthia F. ; Light, Laney ; Ambrosius, Walter T. ; Marcovina, Santica M. ; Probstfield, Jeffrey ; Goff, David C. / The effect of intensive risk factor management in type 2 diabetes on inflammatory biomarkers. In: Diabetes Research and Clinical Practice. 2012 ; Vol. 95, No. 3. pp. 389-398.
@article{390cab04d4ce462c86a07a22eef2f782,
title = "The effect of intensive risk factor management in type 2 diabetes on inflammatory biomarkers",
abstract = "Aims: To determine whether intensive risk factor management reduced markers of inflammation in middle-aged and older people with type 2 diabetes who either had, or were at risk for cardiovascular disease (CVD), and whether these effects were mediated by adiposity. Methods: The Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial was a multicenter double 2 by 2 factorial randomized controlled trial of 10,251 middle-aged and older people who had type 2 diabetes, a GHbA1c of 7.5{\%} or greater, and evidence of CVD or CVD risk factors. Biomarkers were assessed in a subset of 562 participants. Intervention effects on high-sensitivity C-reactive protein (hs-CRP), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-alpha) were tested using linear regression models. Results: A significantly lower average hs-CRP was noted in the intensive versus the standard glycemic group (p=0.029). Adjusting for change in BMI or waist circumference resulted in larger differences in adjusted hs-CRP (p<0.001 and p<0.002, respectively) between the glycemic intervention groups. Conclusions: Intensive glycemic control was associated with a reduction in hs-CRP in this study population. Intervention associated increases in adiposity suppressed the beneficial effect of intensive glycemic control on lowering hs-CRP.",
keywords = "ACCORD trial, Adiposity, CVD, Hs-CRP, Inflammation, Type 2 diabetes",
author = "Samaropoulos, {Xanthia F.} and Laney Light and Ambrosius, {Walter T.} and Marcovina, {Santica M.} and Jeffrey Probstfield and Goff, {David C.}",
year = "2012",
month = "3",
day = "1",
doi = "10.1016/j.diabres.2011.09.027",
language = "English (US)",
volume = "95",
pages = "389--398",
journal = "Diabetes Research and Clinical Practice",
issn = "0168-8227",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

TY - JOUR

T1 - The effect of intensive risk factor management in type 2 diabetes on inflammatory biomarkers

AU - Samaropoulos, Xanthia F.

AU - Light, Laney

AU - Ambrosius, Walter T.

AU - Marcovina, Santica M.

AU - Probstfield, Jeffrey

AU - Goff, David C.

PY - 2012/3/1

Y1 - 2012/3/1

N2 - Aims: To determine whether intensive risk factor management reduced markers of inflammation in middle-aged and older people with type 2 diabetes who either had, or were at risk for cardiovascular disease (CVD), and whether these effects were mediated by adiposity. Methods: The Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial was a multicenter double 2 by 2 factorial randomized controlled trial of 10,251 middle-aged and older people who had type 2 diabetes, a GHbA1c of 7.5% or greater, and evidence of CVD or CVD risk factors. Biomarkers were assessed in a subset of 562 participants. Intervention effects on high-sensitivity C-reactive protein (hs-CRP), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-alpha) were tested using linear regression models. Results: A significantly lower average hs-CRP was noted in the intensive versus the standard glycemic group (p=0.029). Adjusting for change in BMI or waist circumference resulted in larger differences in adjusted hs-CRP (p<0.001 and p<0.002, respectively) between the glycemic intervention groups. Conclusions: Intensive glycemic control was associated with a reduction in hs-CRP in this study population. Intervention associated increases in adiposity suppressed the beneficial effect of intensive glycemic control on lowering hs-CRP.

AB - Aims: To determine whether intensive risk factor management reduced markers of inflammation in middle-aged and older people with type 2 diabetes who either had, or were at risk for cardiovascular disease (CVD), and whether these effects were mediated by adiposity. Methods: The Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial was a multicenter double 2 by 2 factorial randomized controlled trial of 10,251 middle-aged and older people who had type 2 diabetes, a GHbA1c of 7.5% or greater, and evidence of CVD or CVD risk factors. Biomarkers were assessed in a subset of 562 participants. Intervention effects on high-sensitivity C-reactive protein (hs-CRP), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-alpha) were tested using linear regression models. Results: A significantly lower average hs-CRP was noted in the intensive versus the standard glycemic group (p=0.029). Adjusting for change in BMI or waist circumference resulted in larger differences in adjusted hs-CRP (p<0.001 and p<0.002, respectively) between the glycemic intervention groups. Conclusions: Intensive glycemic control was associated with a reduction in hs-CRP in this study population. Intervention associated increases in adiposity suppressed the beneficial effect of intensive glycemic control on lowering hs-CRP.

KW - ACCORD trial

KW - Adiposity

KW - CVD

KW - Hs-CRP

KW - Inflammation

KW - Type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=84857238882&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857238882&partnerID=8YFLogxK

U2 - 10.1016/j.diabres.2011.09.027

DO - 10.1016/j.diabres.2011.09.027

M3 - Article

C2 - 22019270

AN - SCOPUS:84857238882

VL - 95

SP - 389

EP - 398

JO - Diabetes Research and Clinical Practice

JF - Diabetes Research and Clinical Practice

SN - 0168-8227

IS - 3

ER -